Active Biotech Receives Approval for phase II Studies of TASQ

The review of Active Biotech AB's IND, Investigational New Drug, for the TASQ prostate cancer project has been completed by the US Food and Drug Administration, FDA.

A Phase II proof of concept trial in prostate cancer patients will now be initiated, and the first patients in this trial will start treatment before the end of 2007.The approved trial is a randomized, placebo controlled, double-blind Phase II trial investigating 1 mg/day of TASQ versus placebo in 200 patients. The trial will be performed in asymptomatic patients with metastatic, castrate resistant, prostate cancer. This is a similar patient population as that previously treated in the TASQ Phase I program.

For further information please contact:

Sven Andréasson,

President and CEO

Tel: +46 46 19 20 00

Email: sven.andreasson@activebiotech.com

Or visit: www.activebiotech.com